CNS Pharmaceuticals, Inc. received approval from the Spanish agency for medicines and health products (AEMPS) competent authority and from the CElm Provincial de Sevilla Ethics Committee in Spain for the company's potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.204 USD | -4.67% | 0.00% | -83.94% |
Apr. 23 | Transcript : CNS Pharmaceuticals, Inc. - Special Call | |
Apr. 01 | CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-83.94% | 2.17M | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+47.58% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- CNSP Stock
- News CNS Pharmaceuticals, Inc.
- CNS Pharmaceuticals Receives Approval for Pivotal Study of Berubicin for Treatment of Glioblastoma Multiforme